scholarly journals Gamma Knife Radiosurgery-Based Combination Treatment Strategies Improve Survival in Patients With Central Nervous System Metastases From Epithelial Ovarian Cancer: A Retrospective Analysis of Two Academic Institutions in Korea and Taiwan

2021 ◽  
Vol 11 ◽  
Author(s):  
Yen-Ling Lai ◽  
Jun-Hyeok Kang ◽  
Che-Yu Hsu ◽  
Jung-Il Lee ◽  
Wen-Fang Cheng ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Epithelial Ovarian Cancer ◽  
Gamma Knife ◽  
Combination Treatment ◽  
Gamma Knife Radiosurgery ◽  
Disease Relapse ◽  
Cns Involvement ◽  
Cns Metastases

Central nervous system (CNS) metastases from epithelial ovarian cancer (EOC) are rare. We investigated the clinico-pathological prognostic factors of patients with CNS metastases from EOC and compared the outcomes of various treatment modalities. We retrospectively reviewed the records of patients with CNS metastases from EOC between 2000 and 2020. Information on the clinical and pathological characteristics, treatment, and outcomes of these patients was retrieved from Samsung Medical Center and National Taiwan University Hospital. A total of 94 patients with CNS metastases were identified among 6,300 cases of EOC, resulting in an incidence of 1.49%. Serous histological type [hazard ratio (HR): 0.49 (95% confidence interval [CI] 0.25-0.95), p=0.03], progressive disease [HR: 2.29 (95% CI 1.16-4.54), p=0.01], CNS involvement in first disease relapse [HR: 0.36 (95% CI 0.18-0.70), p=0.002], and gamma knife radiosurgery (GKS)-based combination treatment for EOC patients with CNS lesions [HR: 0.59 (95% CI 0.44-0.79), p<0.001] significantly impacted survival after diagnosis of CNS metastases. In a subgroup analysis, superior survival was observed in patients with CNS involvement not in first tumor recurrence who underwent GKS-based combination therapeutic regimens. The survival benefit of GKS-based treatment was not significant in patients with CNS involvement in first disease relapse, but a trend for longer survival was still observed. In conclusion, GKS-based combination treatment can be considered for the treatment of EOC patients with CNS metastases. The patients with CNS involvement not in first disease relapse could significantly benefit from GKS-based combination strategies.

Central Nervous System Metastases from Primary Epithelial Ovarian Cancer

2003 ◽  
Vol 10 (3) ◽  
pp. 244-253 ◽  
Author(s):  
Lalit Kumar ◽  
Suchitra Barge ◽  
Ashok K. Mahapatra ◽  
Sanjay Thulkar ◽  
Gaura Kishore Rath ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Epithelial Ovarian Cancer ◽  
Central Nervous System Metastases ◽  
Primary Epithelial Ovarian Cancer

scholarly journals RT-23 * THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS

2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v192-v192
Author(s):  
K. Mori ◽  
Y. Chiba ◽  
S. Toyota ◽  
T. Kumagai ◽  
S. Yamamoto ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery

Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer

2008 ◽  
Vol 108 (3) ◽  
pp. 505-509 ◽  
Author(s):  
Yoo-Kyung Lee ◽  
Noh-Hyun Park ◽  
Jae Weon Kim ◽  
Yong-Sang Song ◽  
Soon-Beom Kang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Brain Metastases ◽  
Epithelial Ovarian Cancer ◽  
Gamma Knife ◽  
Treatment Modality ◽  
Gamma Knife Radiosurgery ◽  
Optimal Treatment

Central Nervous System Metastases From Epithelial Ovarian Cancer

2011 ◽  
Vol 21 (5) ◽  
pp. 816-821 ◽  
Author(s):  
Gennaro Cormio ◽  
Vera Loizzi ◽  
Maddalena Falagario ◽  
Antonio Calace ◽  
Antonio Colamaria ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Epithelial Ovarian Cancer ◽  
Central Nervous System Metastases

Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship

2015 ◽  
Vol 25 (7) ◽  
pp. 1232-1238 ◽  
Author(s):  
Amelia M. Jernigan ◽  
Haider Mahdi ◽  
Peter G. Rose
Keyword(s):  
Ovarian Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Genetic Testing ◽  
Family History ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcomes ◽  
Breast And Ovarian Cancer ◽  
Cns Metastasis ◽  
Potential Relationship

ObjectivesTo estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival.Methods and MaterialsA total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC− based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used.ResultsOf 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56–78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0–187.91) months. At a median survival of 5.97 (95% CI, 0.20–116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 women died of disease. Univariate Cox proportional hazard models were used to compare HBOC− to HBOC+ women and did not reveal a significant difference for survival outcomes.ConclusionsConfirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so.

Gamma Knife Radiosurgery in AIDS-Related Primary Central Nervous System Lymphoma

1995 ◽  
Vol 64 (1) ◽  
pp. 42-55 ◽  
Author(s):  
A. Nicolato ◽  
M.A. Gerosa ◽  
R. Foroni ◽  
E. Piovan ◽  
P.G. Zampieri ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Central Nervous System Lymphoma

scholarly journals Neurosarcoidosis following Immune Checkpoint Inhibition

2018 ◽  
Vol 11 (2) ◽  
pp. 521-526 ◽  
Author(s):  
Anastasie M. Dunn-Pirio ◽  
Suma Shah ◽  
Christopher Eckstein
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Relevant Literature ◽  
Checkpoint Inhibition ◽  
Immune Checkpoint Inhibition ◽  
Cns Involvement ◽  
Cns Metastases

Recently, immune checkpoint inhibitors have revolutionized cancer care by enhancing anti-tumor immunity. However, by virtue of stimulating the immune system, they can lead to immune-related adverse events (irAEs). Neurologic irAEs are uncommon but are becoming increasingly recognized and can be quite serious or even fatal. Furthermore, central nervous system (CNS) manifestations may be difficult to distinguish from CNS metastases, posing management challenges. Here, we describe a patient who developed exacerbation of sarcoidosis leading to CNS involvement following dual checkpoint blockade with nivolumab and ipilimumab for metastatic melanoma and review the relevant literature.

scholarly journals Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer

Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3408
Author(s):  
Giulia Scotto ◽  
Fulvio Borella ◽  
Margherita Turinetto ◽  
Valentina Tuninetti ◽  
Anna A. Valsecchi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Epithelial Ovarian Cancer ◽  
Hormone Receptors ◽  
Central Nervous System Involvement ◽  
Figo Stage ◽  
The Central Nervous System

Epithelial ovarian cancer (EOC) is the leading cause of death among women affected by gynaecological malignancies. Most patients show advanced disease at diagnosis (FIGO stage III-IV) and, despite the introduction of new therapeutic options, most women experience relapses. In most cases, recurrence is abdominal-pelvic; however, EOC can occasionally metastasize to distant organs, including the central nervous system. The incidence of brain metastases (BMs) from EOC is low, but it has grown over time; currently, there are no follow-up strategies available. In the last decade, a few biomarkers able to predict the risk of developing BMs from OC or as potential therapeutic targets have been investigated by several authors; to date, none have entered clinical practice. The purpose of this review is to offer a summary on the role of the most relevant predictors of central nervous system (CNS) involvement (hormone receptors; BRCA; MRD1; PD-1/PD-L1) and to highlight possible therapeutic strategies for the management of metastatic brain disease in EOC

Sign in / Sign up

Export Citation Format

Share Document